GENE ONLINE|News &
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
On September 1st, BeiGene announced that the FDA has greenlit its Brukinsa (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) for treating adult patients with a rare type of lymphoma called Waldenström’s macroglobulinemia (WM).
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.
GO Prime with only $1.49 now
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
